Page last updated: 2024-09-02

fingolimod hydrochloride and triazoles

fingolimod hydrochloride has been researched along with triazoles in 2 studies

Compound Research Comparison

Studies (fingolimod hydrochloride)	Trials (fingolimod hydrochloride)	Recent Studies (post-2010) (fingolimod hydrochloride)	Studies (triazoles)	Trials (triazoles)	Recent Studies (post-2010) (triazoles)
2,771	157	2,062	25,808	2,252	13,501

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chan, ML; Chan, SH; Chang, WL; Chou, YL; Guh, JH; Hou, DR; Hsu, JL; Hsu, LC; Leu, WJ; Liu, SP; Swain, ShP; Yu, CC	1
Chen, Z; Doyle, TM; Grenald, SA; Largent-Milnes, TM; Salvemini, D; Slosky, LM; Spiegel, S; Vanderah, TW; Zhang, H	1

Other Studies

2 other study(ies) available for fingolimod hydrochloride and triazoles

Article	Year
Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways. Oncotarget, 2016, 11-22, Volume: 7, Issue:47 Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Signal Transduction; Small Molecule Libraries; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays	2016
Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation. Pain, 2017, Volume: 158, Issue:9 Topics: Animals; Breast Neoplasms; Cancer Pain; Cell Line, Tumor; Disease Models, Animal; Female; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Immunosuppressive Agents; Interleukin-10; Mice; Mice, Inbred C57BL; Neurogenic Inflammation; Proprotein Convertases; Receptors, Lysosphingolipid; Serine Endopeptidases; Signal Transduction; Sphingosine-1-Phosphate Receptors; Spinal Cord; Sulfones; Triazoles	2017

Article

Year

Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.

Oncotarget, 2016, 11-22, Volume: 7, Issue:47

Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Signal Transduction; Small Molecule Libraries; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays

2016

Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation.

Pain, 2017, Volume: 158, Issue:9

Topics: Animals; Breast Neoplasms; Cancer Pain; Cell Line, Tumor; Disease Models, Animal; Female; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Immunosuppressive Agents; Interleukin-10; Mice; Mice, Inbred C57BL; Neurogenic Inflammation; Proprotein Convertases; Receptors, Lysosphingolipid; Serine Endopeptidases; Signal Transduction; Sphingosine-1-Phosphate Receptors; Spinal Cord; Sulfones; Triazoles

2017